Mowery, Y. M., Ballman, K. V., Riedel, R. F., Brigman, B. E., Attia, S., Meyer, C. F., … Kirsch, D. G. (2018). SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. In Journal of Clinical Oncology (Vol. 36, pp. TPS11588–TPS11588). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps11588

Mowery, Yvonne Marie, Karla V. Ballman, Richard F. Riedel, Brian E. Brigman, Steven Attia, Christian Frederick Meyer, Scott Schuetze, et al. “SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.” In Journal of Clinical Oncology, 36:TPS11588–TPS11588. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps11588.

Mowery YM, Ballman KV, Riedel RF, Brigman BE, Attia S, Meyer CF, et al. SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS11588–TPS11588.

Mowery, Yvonne Marie, et al. “SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS11588–TPS11588. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps11588.

Mowery YM, Ballman KV, Riedel RF, Brigman BE, Attia S, Meyer CF, Schuetze S, Burgess MA, Chmielowski B, Dickson MA, Hartner LP, Milhem MM, Tinoco G, Van Tine BA, Wagner AJ, Reinke DK, Kirsch DG. SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS11588–TPS11588.